Evaluation of PDZD11 in hepatocellular carcinoma: prognostic value and diagnostic potential in combination with AFP.

IF 3.5 3区医学 Q2 ONCOLOGY Frontiers in Oncology Pub Date : 2025-03-25 eCollection Date: 2025-01-01 DOI:10.3389/fonc.2025.1533865

Yiyun Ni, Bin Liu, Weizhen Zhang, Yilin Pang, Yaling Tian, Qingsong Lv, Shengwen Shi, Yang Zheng, Huihui Fan

{"title":"Evaluation of PDZD11 in hepatocellular carcinoma: prognostic value and diagnostic potential in combination with AFP.","authors":"Yiyun Ni, Bin Liu, Weizhen Zhang, Yilin Pang, Yaling Tian, Qingsong Lv, Shengwen Shi, Yang Zheng, Huihui Fan","doi":"10.3389/fonc.2025.1533865","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is the most prevalent liver cancer, with a 5-year survival rate below 20% and an average survival time of 3-6 months. Identifying new biomarkers is crucial for early diagnosis and prognosis. The function of PDZ domain protein 11 (PDZD11) in HCC remains unclear.Methods: In this study, PDZD11 was investigated as a potential biomarker for HCC using bioinformatic analysis of the TCGA and ICGC datasets. Furthermore, we assessed the potential of serum PDZD11 as a clinical diagnostic marker by enrolling a cohort comprising 78 HCC patients and 62 healthy controls (HC) using the ELISA analysis and combining its expression with common tumor markers.Results: Our research found significantly higher PDZD11 mRNA expression in HCC tissues compared to tumor-adjacent tissues (p < 0.001), which was associated with lower overall survival (OS) rates (p < 0.01). Multivariate evaluation methods established PDZD11 as a standalone predictor of prognosis. A nomogram incorporating PDZD11 expression and clinicopathological factors predicted OS rates for HCC patients over various years. Patients with HCC exhibited notably elevated serum PDZD11 levels compared to HC, with these levels rising further in advanced disease stages and deteriorating performance status (PS). ROC analysis showed high diagnostic accuracy when PDZD11 is combined with AFP (AUC = 0.958).Conclusion: PDZD11 is more sensitive than AFP in assessing HCC prognosis. In conclusion, PDZD11 is a promising supplementary biomarker for HCC diagnosis and prognosis alongside AFP.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1533865"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975663/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1533865","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) is the most prevalent liver cancer, with a 5-year survival rate below 20% and an average survival time of 3-6 months. Identifying new biomarkers is crucial for early diagnosis and prognosis. The function of PDZ domain protein 11 (PDZD11) in HCC remains unclear.

Methods: In this study, PDZD11 was investigated as a potential biomarker for HCC using bioinformatic analysis of the TCGA and ICGC datasets. Furthermore, we assessed the potential of serum PDZD11 as a clinical diagnostic marker by enrolling a cohort comprising 78 HCC patients and 62 healthy controls (HC) using the ELISA analysis and combining its expression with common tumor markers.

Results: Our research found significantly higher PDZD11 mRNA expression in HCC tissues compared to tumor-adjacent tissues (p < 0.001), which was associated with lower overall survival (OS) rates (p < 0.01). Multivariate evaluation methods established PDZD11 as a standalone predictor of prognosis. A nomogram incorporating PDZD11 expression and clinicopathological factors predicted OS rates for HCC patients over various years. Patients with HCC exhibited notably elevated serum PDZD11 levels compared to HC, with these levels rising further in advanced disease stages and deteriorating performance status (PS). ROC analysis showed high diagnostic accuracy when PDZD11 is combined with AFP (AUC = 0.958).

Conclusion: PDZD11 is more sensitive than AFP in assessing HCC prognosis. In conclusion, PDZD11 is a promising supplementary biomarker for HCC diagnosis and prognosis alongside AFP.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PDZD11在肝细胞癌中的评价：联合AFP的预后价值和诊断潜力。

背景：肝细胞癌（HCC）是最常见的肝癌，5年生存率低于20%，平均生存时间为3-6个月。识别新的生物标志物对早期诊断和预后至关重要。PDZ结构域蛋白11 （PDZD11）在HCC中的功能尚不清楚。方法：在本研究中，通过TCGA和ICGC数据集的生物信息学分析，研究PDZD11作为HCC的潜在生物标志物。此外，我们通过ELISA分析纳入了78名HCC患者和62名健康对照（HC），并将其表达与常见肿瘤标志物相结合，评估了血清PDZD11作为临床诊断标志物的潜力。结果：我们的研究发现，HCC组织中PDZD11 mRNA的表达明显高于肿瘤邻近组织（p < 0.001），并且与较低的总生存率（OS）相关（p < 0.01）。多变量评价方法确定PDZD11为预后的独立预测因子。结合PDZD11表达和临床病理因素的nomogram预测HCC患者在不同年份的OS率。与HC相比，HCC患者血清PDZD11水平明显升高，在疾病晚期和表现状态恶化（PS）时，这些水平进一步升高。ROC分析显示PDZD11联合AFP诊断准确率较高（AUC = 0.958）。结论：PDZD11在肝癌预后评估中的敏感性高于AFP。综上所述，PDZD11是一种有希望与AFP一起用于HCC诊断和预后的补充生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.